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ABSTRACT Incontrastwithmost inhalational anesthetics, theanestheticgasesxenon (Xe)andnitrousoxide (N2O)act byblocking
theN-methyl-D-aspartate (NMDA) receptor. Using x-ray crystallography,weexamined the bindingcharacteristics of these twogases
on two soluble proteins as structural models: urate oxidase, which is a prototype of a variety of intracellular globular proteins, and
annexinV,whichhas structural and functional characteristics that allow it to beconsideredasaprototype for theNMDA receptor. The
structure of these proteins complexedwithXe andN2Owere determined.OneN2Omolecule or oneXeatombinds to the samemain
site in both proteins. A second subsite is observed for N2O in each case. The gas-binding sites are always hydrophobic ﬂexible
cavities buried within themonomer. Comparison of the effects of Xe and N2O on urate oxidase and annexin V reveals an interesting
relationshipwith the in vivo pharmacological effects of these gases, the ratio of the gas-binding sites’ volumeexpansion and the ratio
of the narcotic potency being similar. Given these data, we propose that alterations of cytosolic globular protein functions by general
anesthetics would be responsible for the early stages of anesthesia such as amnesia and hypnosis and that additional alterations
of ion-channel membrane receptor functions are required for deeper effects that progress to ‘‘surgical’’ anesthesia.
INTRODUCTION
The mechanisms by which general anesthetics produce their
action on the central nervous system are only now beginning
to be discovered. This is because general anesthesia is a
complex process that does not refer to one but to several
physiologically altered functions. Early stages of anesthesia,
such as amnesia and hypnosis, are produced at anesthetic
concentrations lower than those required to produce deep
sedation and reduction of motor and autonomic responses to
noxious stimuli (1). The Meyer-Overton rule of a high cor-
relation between anesthetic potency and hydrophobicity has
for a long time promoted the hypothesis that anesthetics act
by disrupting the structure and dynamics of lipid membranes
(2). However, there is now a general consensus that general
anesthetics act by disrupting protein functions (3,4). Even if
general anesthetics have been shown to interact with glob-
ular proteins in a manner consistent with the Meyer-Overton
rule (5,6), the proteins considered as their most likely mo-
lecular targets at clinically relevant concentrations are ion-
channel receptors (4,7). The current opinion is that general
anesthetics act by enhancing the activity of inhibitory re-
ceptors and by inhibiting the activity of excitatory recep-
tors (1). The main target of most inhalational anesthetics is
considered to be the g-amino-butyric acid type A (GABAA)
inhibitory receptor (8–10). In contrast, xenon (Xe) and
nitrous oxide (N2O), which are gaseous anesthetics, are most
efﬁcient against the N-methyl-D-aspartate (NMDA) excita-
tory receptor and to a lesser extent against the neuronal
nicotinic receptor and the TREK-1 two-pore K1 channel
(11–14). In addition, it should be mentioned that a recent
study has identiﬁed the existence of a speciﬁc gas channel
that may serve to accelerate gas action (15), but the relevance
of this ﬁnding to general anesthesia still remains to be dem-
onstrated.
Scales that assess the in vivo potency of inhaled an-
esthetics in humans are based on the minimum alveolar
anesthetic concentrations (MAC) that are associated with
well-deﬁned behavioral endpoints. For example, MAC-
awake deﬁnes the MAC that prevents voluntary responses to
spoken commands, i.e., the impairment of perceptive aware-
ness to environmental stimuli (hypnosis), and MAC-immo-
bility deﬁnes the MAC that produces deep sedation and
suppresses purposeful movement in response to a standard
noxious stimulus (1). Likewise, laboratory animals can be
assessed for MAC-immobility. Although MAC-awake can,
in the strict sense, be measured only in humans, anesthetic-
induced loss of the righting reﬂex in animals is considered a
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behavioral endpoint for which the dependence on anesthetic
concentration is closely related to MAC-awake (1).
Although the potency of inhalational anesthetics is usually
in accord with the Meyer-Overton rule, there are a number
of alterations and exceptions that emphasize the complexity
of the molecular routes through which these anesthetic
compounds act. For example, the so-called nonimmobilizers,
which are large halogenated alkanes predicted to be potent
anesthetics by the Meyer-Overton rule, produce amnesia but
lack of immobilizing activity (16). And whereas the ratio of
MAC-awake for N2O and Xe is ;1.4 (17–19), with respect
to the Meyer-Overton rule, the ratio of MAC-immobility for
these gases is only 1 (19–22). Then, it is likely that the early
stages of anesthesia and the deeper effects that progress to
‘‘surgical’’ anesthesia are mediated by separate sites and
mechanisms (23,24).
With plausible inhalational anesthetic targets now identi-
ﬁed, current investigations attempt to determine which
targets are actually responsible for the different and multiple
stages of anesthesia. Unfortunately, at the structural biology
level, no one structure is known today for proteins thought to
be anesthetic targets. Structural investigations on particular
soluble proteins chosen as close models may be an approach
to understand the binding mode of inhalational anesthetics
and to appreciate the molecular changes that these gases
produce on their targets (21).
To identify and compare the binding characteristics of
N2O and Xe, we performed x-ray crystallography studies on
two structural models, urate oxidase and annexin V. Urate
oxidase is a prototype of a variety of intracellular globu-
lar proteins that possess large hydrophobic cavities (25).
Annexin V is a protein that binds to biological membranes
in a reversible calcium-dependent manner and possesses a
hydrophilic pore, believed to be the calcium conduction
pathway, that lies at the interface of four homologous and
structurally related domains (26). These structural charac-
teristics and functional properties of ion selectivity and
voltage gating allow annexin V to be considered as a pro-
totype for the NMDA receptor (27,28). Xe, but not N2O,
binding ability to urate oxidase has already been studied
(29). No structure of annexin V with gas has ever been
solved before. Although argon and krypton have been shown
to bind to the same site as Xe in two examples of globular
proteins (30,31), our investigations in urate oxidase and
annexin V were restricted to Xe and N2O, which mainly act
by inhibiting the NMDA receptor (11–13) because argon and
krypton do not seem to exert their effect through this receptor
(32,33). In a recent study, Miller indicated that the gas
pressure for crystallography studies should be at least 10 times
higher than their physiological concentration to approximate
binding saturation (24). In the study presented here, we
identiﬁed discrete binding sites for Xe and N2O at 2 MPa (or
20 bar) and further demonstrated that the gas-binding cavities’
expansion ratios in urate oxidase and annexin V are consistent
with the in vivo physiological effects of these gases.
MATERIALS AND METHODS
Crystals of Aspergillus ﬂavus urate oxidase, a tetrameric peroxisomal protein
of 135 kDa, complexed with its inhibitor, 8-azaxanthin, and crystals of rat
annexin V, a trimeric protein of 105 kDa, in high calcium concentration were
grown as described previously (34,35). The method used to prepare Xe
complexes has been described earlier (36). N2O complexes were prepared
similarly. Native crystal, mounted in a quartz capillary, ﬁtted to a specially
designed cell, was submitted to gas pressure a few minutes before the start of
data collection. A gas pressure of 2 MPa was maintained during the data
collection. Diffraction data were collected at the DW32 wiggler beam line
at the LURE synchrotron facility in Orsay, France, using x-rays at a
wavelength of 0.964 A˚ and a 345-mm MAR-Research image plate detector,
and at the ESRF (Grenoble, France) BM14 beamline, at a wavelength of
0.972 A˚ and operating in a 16-bunch mode, using a MAR CCD detector;
temperature was set to 277 K in all cases. Data were integrated by DENZO
and scaled independently using SCALEPACK, both programs from the HKL
package (37). Data reduction and reindexing when necessary were carried
out with programs of the CCP4 package (38). Structure reﬁnements were
carried out by REFMAC from the CCP4 package (39). The starting model
for urate oxidase rigid body reﬁnement was the PDB entry 1R51 (resolution
1.75 A˚) (40), and the starting model for annexin V reﬁnement was the PDB
entry 1A8A (resolution 1.90 A˚) (41). In all cases, solvent, ion, and/or
inhibitor molecules were removed from the original model. The graphic
program O (42) was used to visualize the 2Fobs-Fcalc and the Fobs-Fcalc
electron-density maps and for manual rebuilding. A summary of the data
collections and reﬁnement parameters is shown in Table 1. The gas com-
plexes have been compared to the native structures collected in parallel.
Cavity volumes were calculated with the program VOIDOO (43). The
following parameters gave the most reliable results for both proteins with the
lowest mean deviation: primary grid spacing, 0.6 A˚; grid spacing, 0.6 A˚;
probe radius, 1.0 A˚. Slightly different results were obtained when different
orientations of the model were used. Thus, the accuracy of cavity volume
calculations and the mean deviation were estimated by repeating the
calculations on nine randomly oriented copies of the model. To check
whether the cavity volume expansion ratios are dependent or not on the
methods used, the different structures were also reﬁned in parallel with
SHELXL from the SHELX-97 package (44), and cavities’ volumes were sim-
ilarly calculated using the program CASTp (45) with a probe radius of 1.3 A˚
for a reliable estimation of the cavity volume.
RESULTS
The four complexes studied (urate oxidase with Xe and N2O
and annexin V with Xe and N2O) were solved at a resolution
better than 1.75 A˚, allowing unambiguous detection of the
bound gas (Fig. 1). The complex urate oxidase-Xe has
already been solved, but at a lower resolution because Xe has
been used as a heavy atom derivative for the initial structure
resolution (25). It was shown that Xe binds to urate oxidase
in a unique site with an occupancy factor sufﬁcient to solve
the structure. It is conﬁrmed in this case that Xe is located at
the same place, just behind the active site, with an occupancy
evaluated at;0.9 (Fig. 1 A). In the case of annexin V, it was
the ﬁrst time that a complex with Xe was analyzed. Xe binds
to a unique site, a hydrophobic cavity located in the center of
the third domain, with an occupation factor of ;0.4 (Fig.
1 C). In these two proteins, Xe binds to a preexisting
hydrophobic ﬂexible gas cavity buried within the monomer
with no visible water. No structural studies of proteins with
N2O have been reported until the investigation presented
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here, to our knowledge. N2O binds to urate oxidase in the
same cavity as Xe, with a lower occupation factor of ;0.7
(Fig. 1 B). N2O also binds to annexin V in the same site as
Xe, but with a higher occupation factor evaluated at ;0.9
(Fig. 1 D). Thus, in the two proteins, a molecule of N2O is
found exactly at the same location as the Xe atom, showing
that N2O shares some physicochemical properties with
Xe. However, in both proteins, a second N2O molecule is
observed. In urate oxidase, this second molecule is found
within the same hydrophobic cavity, orthogonally oriented
with respect to the ﬁrst one, with a lower occupation factor of
;0.6 (Fig. 1 B). In annexin V, the second molecule, with an
occupation factor of 0.7, is found in another hydrophobic
cavity located in the center of the ﬁrst domain (Fig. 1 E). In
the annexin V-Xe complex, this cavity is empty. In all cases,
the bound gas is surrounded by ﬁve or six side-chain carbon
atoms from aliphatic residues at,4.5 A˚ for the Xe atom and
at ,4.0 A˚ for the two N2O molecules (Table 2). The overall
protein structures showed, as expected, very little perturba-
tion on gas binding, with an overall root mean-square
deviation ,0.15 A˚ for the backbone and ,0.40 A˚ for all
protein atoms. However, contrary to what was expected
(pressure should lead to a volume compression), both Xe and
N2O produce a volume expansion of the cavities where they
bind, resulting from slight displacements of the side chain
atoms lining the cavities.
In urate oxidase, Xe induces a volume increase of 23.5%.
Matthews and co-workers (30) found a similar expansion
effect of Xe in the globular phage T4 lysozyme structure.
N2O induces a volume expansion of 17.9%, leading to a ratio
of volume expansion for Xe and N2O of 1.32 (Table 3).
Equivalent ratio values are obtained when the structures are
independently reﬁned with SHELXL instead of REFMAC
(ratio of 1.44), cavity volumes calculated with CASTp
instead of VOIDOO (ratio of 1.51), or SHELXL and CASTp
used simultaneously (ratio of 1.25), thereby leading to an
average ratio of volume expansion of 1.38 (data not shown).
In annexin V, Xe and N2O respectively induce volume
expansions of their primary binding site of 14.1% and
32.1%, leading to a ratio of volume expansion for Xe and
N2O of 0.44 (Table 3). Equivalent ratio values are obtained
when the structures are independently reﬁned with SHELXL
instead of REFMAC (ratio of 0.58), cavity volumes calcu-
lated with CASTp instead of VOIDOO (ratio of 0.46), or
SHELXL and CASTp used simultaneously (ratio of 0.36),
thereby leading to an average ratio of volume expansion of
0.46 (data not shown); in addition, N2O also expands the
volume of its secondary binding site by 33.0% (Table 3).
TABLE 1 Crystallographic data collections and reﬁnement statistics
Protein Urate oxidase Annexin V
Gas – Xe N2O – Xe N2O
Data collection
Space group I222 I222 I222 H3 H3 H3
Unit cell parameters (A˚)
a 80.49 80.50 80.19 156.98 156.99 157.03
b 96.04 96.58 96.03 156.98 156.99 157.03
c 105.34 106.01 105.21 37.48 37.34 37.33
Resolution range (A˚) 50–1.5 20–1.75 70–1.75 78–1.74 78–1.83 78–1.74
Unique reﬂections 59653 34588 41239 32838 25958 34281
(Final shell) (5710) (1813) (4076) (3387) (2674) (2953)
Overall Rsym*(%) 5.6 4.9 5.5 4.6 5.1 4.5
(Final shell) (27.1) (5.3) (34.6) (20.2) (25.8) (17.8)
Completeness (%) 91.1 82.5 99.9 92.9 85.8 97.3
(Final shell) (87.9) (44.3) (99.8) (95.5) (88.3) (83.2)
Reﬁnement statistics (REFMAC)
Resolution range 20–1.5 20–1.7 20–1.7 20–1.7 20–1.8 20–1.7
Rvalue
y(%) 17.63 16.72 16.29 17.04 16.78 17.39
Rfree
z(%) 19.77 19.94 18.56 19.24 19.85 20.19
ÆBæ for protein atoms§(A˚2) 19.89 20.05 21.97 25.68 27.13 29.21
ÆBæ for waters{(A˚2) 31.98 30.33 34.70 34.03 33.47 37.26
Weighted rmsd from ideality
Bond length (A˚) 0.010 0.014 0.013 0.012 0.013 0.013
Bond angle () 1.41 1.50 1.60 1.43 1.47 1.47
PDB code 2IBA 2IC0 2ICQ – 2IE6 2IE7
*Rsym is deﬁned as +h;k;l+i jIiðh; k; lÞ  Iiðh; k; lÞj=+h;k;l+i Iiðh; k; lÞ where Ii(h,k,l) is the ith observation of reﬂection h,k,l and ÆI(h,k,l)æ is the weighted
mean of all observations (after rejection of outliers).
yRvalue is deﬁned as +jFoj  jFcj=+jFoj and indicates the accuracy of the model.
zRfree is a cross validation residual calculated using 10% of the native data, which were randomly chosen and excluded from the reﬁnement.
§Includes inhibitor atoms for urate oxidase.
{Includes gas for urate oxidase and includes calcium ion, sulfate ion, and gas for annexin V.
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When we consider the effects of Xe and N2O on urate
oxidase and annexin V together as a model of simultaneous
occupation of cytosolic and membrane proteins by Xe or
N2O (see the discussion section about the implications for
general anesthesia mechanisms), we ﬁnd an overall expan-
sion of the gas-binding cavities of 20.6% in presence of Xe
and of 22.2% in presence of N2O, leading to an expansion
ratio of 0.93 (Table 3). Equivalent ratio values are obtained
when the structures are independently reﬁned with SHELXL
instead of REFMAC (ratio of 1.14), cavity volumes calcu-
lated with CASTp instead of VOIDOO (ratio of 1.09), or
SHELXL and CASTp used simultaneously (ratio of 0.96),
thereby leading to an average ratio of volume expansion of
1.03 (data not shown).
DISCUSSION
Many Xe-protein complexes have been solved, showing that
Xe atoms bind not only to intramolecular cavities but also to
intermolecular sites or exposed pockets (29,46). However, in
the majority of cases, Xe binds to inaccessible hydrophobic
preexisting ﬂexible gas cavities. Here, we show that the
primary binding sites of Xe and N2O within two soluble
proteins, urate oxidase and annexin V, are identical ﬂexible
gas cavities with no visible water. Even if the pressure used
is higher than any physiological pressure used in anesthesia
because of the x-ray crystallography technique, which needs
an elevated gas pressure to saturate the site for direct ob-
servation (24), we can draw the hypothesis that these two
gases would bind to the same site within their main phys-
iological target, the pore of the NMDA receptor. We chose to
study these gases at a same pressure of 2 MPa for a more
rational comparison of their effects.
Implication for protein function
Internal cavities within proteins are crucial for conforma-
tional ﬂexibility and domain motion (47,48) and thereby for
protein and cell functions. A ligand can reach a buried cavity
through thermal motion (49). It was proposed that only pro-
teins with large enough preexisting internal cavities can bind
anesthetics (30). Occupation and expansion of large hydro-
phobic ﬂexible gas cavities within intracellular or membrane
FIGURE 1 Omit maps of the two
gases within the two proteins. Omit
maps showing the position of the Xe
atom (A) or of the two N2O molecules
(B) within urate oxidase binding site
cavity. Omit maps showing the position
of the Xe atom (C), the ﬁrst N2O
molecule (D), and the second N2O
molecule (E) in annexin V. (Contour
levels at 3 SD above the average
background.)
TABLE 2 Closest contacts (in A˚) around the xenon atom (Xe),
the nitrous oxide molecule (N2O (1)) located at the same
position as the Xe atom and the second nitrous oxide molecule
(N2O (2)) in urate oxidase (see Fig. 2) and annexin V (see Fig. 3)
Urate oxidase Annexin V
Xe 3.91 Cd2 Leu-252 Xe 2.93 Cg2 Thr-227
3.95 Cd2 Leu-252 3.65 Cd2 Phe-192
4.09 Cd1 Phe-219 3.86 Cd1 Leu-235
4.29 Cd2 Leu-178 3.90 Cg2 Thr-287
4.30 Cg1 Val-227 3.99 Cb Glu-226
4.43 Ce Met-234
N2O (1) 3.25 Cg2 Thr-230 N2O (1) 3.23 Cg2 Thr-227
3.50 Cg Thr-180 3.42 Cg Phe-192
3.52 Cd2 Leu-178 3.49 Cd1 Leu-235
3.59 Cd Leu-252 3.65 Cg2 Thr-187
3.77 Cg1 Val-227 3.85 Cb Glu-223
3.81 Ce1 Phe-219
N2O (2) 3.19 Cb Phe-219 N2O (2) 3.32 Cg2 Val-80
3.32 Cg2 Thr-215 3.36 Cg1 Val-64
3.33 Cg2 Val-182 3.43 Cb Met-67
3.50 Ce Met-234 3.51 Cg2 Ile-79
3.50 Cg2 Thr-180 3.75 O Glu-76
3.83 Cd1 Leu-71
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proteins may therefore lead to conformational rigidity,
thereby disrupting protein and cell functions. In urate oxi-
dase, we found that the gas-binding cavity is situated near the
active site where the competitive inhibitor, 8-azaxanthin,
binds (Fig. 2). It is then plausible that occupation and expan-
sion by Xe or N2O of this large hydrophobic gas-binding
cavity may restrain or disrupt the catalytic activity of urate
oxidase. As regards annexin V, the native structure is known
at high and low calcium concentration (35,50), showing a
calcium-induced large-scale conformational movement
within the third domain of the protein. The loop carrying a
tryptophan residue buried within the core of this domain
moves, making the tryptophan solvent-accessible and ready
to bind to membrane lipids. In parallel, a glutamate residue
switches to a position where it is ready to bind the calcium
ion (Fig. 3). This hinge movement, believed to open the
calcium ion path, is a key step for the protein ﬁxation to and
detachment from the membrane and all its functional roles
(51,52). In the annexin-gas complexes solved here at high
calcium concentration, both Xe and N2O bind within the
hydrophobic cavity left vacant by the outer solvent-acces-
sible position of the tryptophan. It is then plausible that
occupation and expansion of this cavity by Xe and N2O
would prohibit the hinge movement of the loop necessary for
all annexin V functions, thereby disrupting them. These ﬁnd-
ings and their plausible consequences on protein functioning
are in agreement with previous experiments showing that
binding of anesthetics leads to an increase in protein stability
(53) and to a reduction of kinetics in single nicotinic acetyl-
choline channels (54). This receptor possesses a structure
close to that of the NMDA ion-channel receptor, which is
known to be a main target for Xe and N2O (11–13). By
analogy, we suggest that the presence of a gas bound to a
hydrophobic cavity within the transmembrane domain of the
NMDA receptor channel, as shown for the nicotinic acetyl-
choline receptor channel (55), may alter the ﬂexibility of the
pore, thereby limiting calcium exchange and disrupting the
NMDA receptor function. Interestingly, we found that Xe
and N2O bind to a same site in the center of the third domain
of annexin V and that N2O also binds to a second cavity
located in the center of the ﬁrst annexin V domain. This may
be related to recent pharmacological ﬁndings that have sug-
gested that N2O may interact with both the NR1 and NR2D
subunits of the NMDA receptor (56,57), whereas Xe may act
only at the NR2D subunit (57,58).
TABLE 3 Cavities volume (calculated with VOIDOO (43)) for
urate oxidase and annexin V (reﬁned with REFMAC (39)) with
their mean deviation, expansion for xenon (Xe) and nitrous












Cavity 1 119.1 6 2.0
1 Xe 147.1 6 2.5 23.5
1 N2O 140.3 6 2.9 17.9 1.32*
Annexin V
Cavity 1 52.9 6 1.5
1 Xe 60.4 6 1.1 14.1
1 N2O 69.9 6 2.0 32.1 0.44
Cavity 2 31.1 6 1.4
1 N2O 41.4 6 1.1 33.0 –
Cavities 1 1 2 84.0 6 2.9
1 N2O 111.3 6 3.1 32.4 0.44
y
Urate oxidase 1 annexin V
Cavities 1 172.0 6 3.4
1 Xe 207.5 6 3.6 20.6
1 N2O 210.2 6 4.9 22.2 0.93
z
Cavities 1 1 2 203.1 6 4.9
1 N2O 251.6 6 6.0 23.9 0.86
y
*In accord with the relative narcotic potency of Xe compared to N2O when
assessed by loss of the righting reﬂex, a behavioral endpoint whose
dependence on anesthetic concentration is closely related to MAC-awake
(see Table 4).
yCompared to expansion induced by Xe.
zIn accord with the relative anesthetic potency of Xe compared to N2O
when assessed by lack of purposeful movement in response to a noxious
stimulus, an endpoint that allows deﬁning MAC-immobility values (see
Table 4). Equivalent expansion ratio values are obtained when the struc-
tures are independently reﬁned with SHELXL instead of REFMAC, cavity
volumes calculated with CASTp instead of VOIDOO, or SHELXL and
CASTp used simultaneously.
FIGURE 2 Urate oxidase binding sites for Xe or N2O. Smooth carbon
a-chain representation of urate oxidase monomer with the hydrophobic gas-
binding site at close proximity to the active site pocket occupied by the
competitive inhibitor 8-azaxanthin. One atom of Xe or two N2O molecules
bind within the hydrophobic cavity. Oxygen, nitrogen, and Xe atoms are
colored in red, blue, and orange, respectively.
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Implication for the mechanisms of
general anesthesia
The range and average value of the volume expansion ratio
of the gas-binding cavities for Xe and N2O in urate oxidase
(range 1.25–1.51, mean 1.38) ﬁt both with the Meyer-
Overton concept and the ratio of the in vivo effects of these
gases when assessed by the loss of the righting reﬂex (range
1.28–1.49, mean 1.38; see Table 4), a behavioral endpoint
whose dependence on anesthetic concentration is closely re-
lated to MAC-awake (1). This indicates that the concordance
between the volume expansion effects of Xe and N2O and
the in vivo MAC-awake effects of these gases is between
97.5% (1.25:1.28) and 98.5% (1.49:1.51). No similar rela-
tionship is found for annexin V. However, we found that the
range and average value of the volume expansion ratio of the
gas-binding cavities for Xe and N2O in urate oxidase and
annexin V, taken together as a model of simultaneous oc-
cupation of cytosolic and membrane proteins (range 0.93–
1.14, mean 1.03), do ﬁt with the ratio of the in vivo effects of
these gases when assessed by the absence of purposeful
movement in response to noxious stimuli (range 0.95–0.99,
mean 0.97; see Table 4), an endpoint that deﬁnes MAC-
immobility values (1). This indicates that the concordance
between the volume expansion effects of Xe and N2O and
the in vivo MAC-immobility effects of these gases is be-
tween 87% (0.99:1.14) and 98% (0.93:0.95). Whenever such
effects occur in brain cytosolic and membrane receptors,
they may be of physiological signiﬁcance and may help to
reconcile the critical volume expansion theory, initially
developed for membrane lipids, with protein theories of
anesthesia (59).
Based on the data of the study presented here, we hypoth-
esize a step-by-step mechanism of inhaled anesthetic action
in which the graded dose-response effect would depend on
cavity size and order of ﬁlling. Xe and N2O would ﬁrst bind
to brain intracellular proteins possessing large hydrophobic
cavities, which constitute easy targets for inhalational an-
esthetics, thereby disrupting the activity of these proteins in a
manner sufﬁcient to induce moderate neuronal dysfunctions
leading to the early stages of anesthesia, i.e., amnesia and
hypnosis. If gas concentration rises, the smaller hydrophobic
gas-binding cavities within the NMDA receptor would then
begin to be ﬁlled (with the cytosolic protein-binding cavities
FIGURE 3 Annexin V hinge movement and binding
sites of Xe or N2O. Smooth carbon a-chain representation
of annexin V monomer in low- and high-calcium confor-
mation (colored in purple and blue, respectively) showing
the hinge movement of the loop carrying the tryptophan
185 in parallel to the glutamate 226 switch. Both Xe and
N2O bind within the hydrophobic cavity left vacant by the
movement of the tryptophan. A second molecule of N2O
binds in the center of the ﬁrst domain. The color code is the
same as above plus the calcium colored in pink. Figs. 2 and
3 were produced with the visualization software InsightII
(Accelrys, San Diego, CA).
TABLE 4 Mean anesthetic concentration (MAC) of xenon
(Xe) and nitrous oxide (N2O) producing loss of righting










Loss of righting reﬂex
(MAC-awake)
N2O 128 (17) 125
122 (18)
Xe 86 (17) 90.5 1.38
95 (19)






Xe 161 (19) 161 0.97
*The relative anesthetic potency of Xe is expressed compared to the
anesthetic potency of N2O taken as a 100% value. The relative narcotic
potencies of Xe and N2O calculated from the different experimental MAC-
awake and MAC-immobility values range from 1.28 to 1.49 (mean value
1.38) and from 0.95 to 0.99 (mean value 0.97), respectively.
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still fully occupied), thereby disrupting the receptor function
and leading to surgical anesthesia, i.e., deep sedation and
lack of autonomic and motor responses to noxious stimuli.
Similar step-by-step mechanisms of general anesthesia,
which assume a causal link between the behavioral effects
of anesthesia from amnesia and hypnosis to ‘‘surgical
anesthesia’’ and the progressive occupation of the anesthetic
binding sites from globular proteins to ion channel receptors,
may occur for other types of inhaled anesthetics and/or ion-
channel receptors, such as the GABAA receptor, which is
thought to be the molecular target of most volatile an-
esthetics (8–10). Such mechanisms may also explain a
number of critical exceptions to the Meyer-Overton rule of a
high correlation between anesthetic potency and hydropho-
bicity, depending on the relative size of the anesthetics and
of the anesthetic-binding cavities within ion channel recep-
tors. For instance, the so-called nonimmobilizers, predicted
to be potent anesthetics by the Meyer-Overton rule, produce
amnesia but lack of immobilizing activity (16). According to
our model, the large size of the so-called nonimmobilizers
may allow these gases to bind to cytosolic globular proteins
but not to ion channel receptors, which possess smaller
hydrophobic cavities, thereby producing moderate neuronal
dysfunction and leading to the production of amnesia but not
to immobilizing activity.
The authors gratefully thank Bertrand Castro and Mohamed El Hajji
(Sanoﬁ-Aventis, Montpellier, France) for supplying urate oxidase. They
also thank Ce´line Tessier (UMR-5471 Biophysique Structurale, Universite´
Bordeaux1, France) for her expert technical assistance with annexin V pro-
duction. N.C. and T.P. thank Martin Walsh (ESRF, Grenoble, France) for
access to and advice on the BM14 line. N.C. and J.S. thank the CRIHAN
(Rouen, France) and the FEDER for the use of the visualisation software
InsightII (Accelrys, San Diego, CA).
This research was supported by NNOXe Pharmaceuticals, the Direction
Ge´ne´rale de l’Armement (DGA, Ministe`re de la De´fense, Paris, France; con-
tract No. 06co24), Air Liquide, the CNRS, the Universite´ de Caen-Basse-
Normandie, and the Universite´ Paris 5.
REFERENCES
1. Campagna, J. A., K. W. Miller, and S. A. Forman. 2003. Mechanisms
of actions of inhaled anesthetics. N. Engl. J. Med. 348:2110–2124.
2. Janoff, A. S., M. J. Pringle, and K. W. Miller. 1981. Correlation of
general anesthetic potency with solubility in membranes. Biochim.
Biophys. Acta. 649:125–128.
3. Franks, N. P., and W. R. Lieb. 1984. Do general anaesthetics act by
competitive binding to speciﬁc receptors? Nature. 310:599–601.
4. Franks, N. P., and W. R. Lieb. 1994. Molecular and cellular mech-
anisms of general anaesthesia. Nature. 367:607–614.
5. Slater, S. J., K. J. A. Cox, J. V. Lombardi, C. Ho, M. B. Keily, E.
Rubin, and C. D. Stubbs. 1993. Inhibition of protein kinase C by
alcohols and anaesthetics. Nature. 364:82–84.
6. Hemmings, H. C., Jr., and A. I. Adamo. 1994. Effects of halothane and
propofol on puriﬁed brain protein kinase C activation. Anesthesiology.
81:147–155.
7. Narahashi, T., G. L. Aistrup, J. M. Lindstrom, W. Marszalec, K.
Nagata, F. Wang, and J. Z. Yeh. 1998. Ion channel modulation as the
basis for general anesthesia. Toxicol. Lett. 100–101:185–191.
8. Krasowski, M. D., and N. L. Harrison. 1999. General anaesthetic
actions on ligand-gated ion channels. Cell. Mol. Life Sci. 55:1278–
1303.
9. Quinlan, J. J., G. E. Homanics, and L. L. Firestone. 1998. Anesthesia
sensitivity in mice that lack the beta3 subunit of the gamma-
aminobutyric acid type A receptor. Anesthesiology. 88:775–780.
10. Sonner, J. M., M. Cascio, Y. Xing, M. S. Fanselow, J. E. Kralic, A. L.
Morrow, E. R. Korpi, S. Hardy, B. Sloat, E. I. Eger 2nd, and G. E.
Homanics. 2005. Alpha 1 subunit-containing GABA type A receptors
in forebrain contribute to the effect of inhaled anesthetics on condi-
tioned fear. Mol. Pharmacol. 68:61–68.
11. Franks, N. P., R. Dickinson, S. L. de Sousa, A. C. Hall, and W. R.
Lieb. 1998. How does xenon produce anaesthesia? Nature. 396:324.
12. Jevtovic-Todorovic, V., S. M. Todorovic, S. Mennerick, S. Powell, K.
Dikranian, N. Benshoff, C. F. Zorumski, and J. W. Olney. 1998.
Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant
and neurotoxin. Nat. Med. 4:460–463.
13. Yamakura, T., and R. A. Harris. 2000. Effects of gaseous anesthetics
nitrous oxide and xenon on ligand-gated ion channels. Comparison
with isoﬂurane and ethanol. Anesthesiol. 93:1095–1101.
14. Gruss, M., T. J. Bushell, D. P. Bright, W. R. Lieb, A. Mathie, and
N. P. Franks. 2004. Two-pore-domain K1 channels are a novel target
for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol.
Pharmacol. 65:443–452.
15. Khademi, S., J. O’Connell III, J. Remis, Y. Robles-Colmenares, L. J. W.
Miercke, and R. M. Stroud. 2004. Mechanism of ammonia transport
by Amt/MEP/Rh: structure of AmtB at 1.35 A˚. Science. 305:1587–1594.
16. Kandel, L., B. S. Chortkoff, J. Sonner, M. J. Laster, and E. I. Eger II.
1996.Nonanesthetics can suppress learning.Anesth. Analg. 82:321–326.
17. David, H. N., F. Leveille´, L. Chazalviel, E. T. MacKenzie, A. Buisson,
M. Lemaire, and J. H. Abraini. 2003. Reduction of ischemic brain
damage by nitrous oxide and xenon. J. Cereb. Blood Flow Metab.
23:1168–1173.
18. Miller, K. W., M. W. Wilson, and R. A. Smith. 1978. Pressure resolves
two sites of action of inert gases. Mol. Pharmacol. 14:950–959.
19. Koblin, D. D., Z. Fang, E. I. Eger II, M. J. Laster, D. Gong, P. Ionescu,
M. J. Halsey, and J. R. Trudell. 1998. Minimum alveolar concentrations
of noble gases, nitrogen, and sulfur hexaﬂuoride in rats: helium and neon
as nonimmobilizers (nonanesthetics). Anesth. Analg. 87:419–424.
20. Russell, G. B., and J. M. Graybeal. 1992. Direct measurement of
nitrous oxide MAC and neurologic monitoring in rats during anesthesia
under hyperbaric conditions. Anesth. Analg. 75:995–999.
21. Russell, G. B., and J. M. Graybeal. 1995. Differences in anesthetic
potency between Sprague-Dawley and Long-Evans rats for isoﬂurane
but not nitrous oxide. Pharmacology. 50:162–167.
22. Russell, G. B., and J. M. Graybeal. 1998. Nonlinear additivity of
nitrous oxide and isoﬂurane potencies in rats. Can. J. Anaesth. 45:
466–470.
23. Eger II, E. I., D. D. Koblin, R. A. Harris, J. J. Kendig, A. Pohorille,
M. J. Halsey, and J. R. Trudell. 1997. Hypothesis: inhaled anesthetics
produce immobility and amnesia by different mechanisms at different
sites. Anesth. Analg. 84:915–918.
24. Miller, K. W. 2002. The nature of sites of general anaesthetic action.
Br. J. Anaesth. 89:17–31.
25. Colloc‘h, N., M. El Hajji, B. Bachet, G. L’Hermite, M. Schiltz, T.
Prange´, B. Castro, and J. P. Mornon. 1997. Crystal structure of the
protein drug urate oxidase-inhibitor complex at 2.05 A˚ resolution. Nat.
Struc. Biol. 4:947–952.
26. Gerke, V., and S. E. Moss. 2002. Annexins: from structure to function.
Physiol. Rev. 82:331–371.
27. Berendes, R., D. Voges, P. Demange, R. Huber, and A. Burger. 1993.
Structure-function analysis of the ion channel selectivity ﬁlter in human
annexin V. Science. 262:427–430.
28. Demange, P., D. Voges, J. Benz, S. Liemann, P. Go¨ttig, R. Berendes,
A. Burger, and R. Huber. 1994. Annexin V: the key to understanding
ion selectivity and voltage regulation?TrendsBiochem. Sci. 19:272–276.
Xenon and Nitrous Oxide Binding Mode 223
Biophysical Journal 92(1) 217–224
29. Prange´, T., M. Schiltz, L. Pernot, N. Colloc’h, S. Longhi, W. Bourguet,
and R. Fourme. 1998. Exploring hydrophobic sites in proteins with
xenon or krypton. Proteins. 30:61–73.
30. Quillin, M. L., W. A. Breyer, I. J. Griswold, and B. W. Matthews.
2000. Size versus polarizability in protein-ligand interactions: binding
of noble gases within engineered cavities in phage T4 lysozyme. J. Mol.
Biol. 302:955–977.
31. Schiltz, M., R. Fourme, and T. Prange´. 2003. Use of noble gases xenon
and krypton as heavy atoms in protein structure determination. Methods
Enzymol. 374:83–119.
32. Abraini, J. H. 2001. Etude des Parame`tres Cine´tiques des Gaz Inertes:
Azote, Argon, Krypton, Protoxyde d’Azote et Xe´non.: Air Liquide
Sante´ International, Paris, France.
33. Abraini, J. H., B. Kriem, N. Balon, J. C. Rostain, and J. J. Risso. 2003.
Gamma-aminobutyric acid neuropharmacological investigations on
narcosis produced by nitrogen, argon, or nitrous oxide. Anesth. Analg.
96:746–749.
34. Bonnete´, F., D. Vivare`s, C. Robert, and N. Colloc’h. 2001. Interactions
in solution and crystallization of Aspergillus ﬂavus urate oxidase.
J. Crystal Growth. 232:330–339.
35. Sopkova, J., M. Renouard, and A. Lewit-Bentley. 1993. The crystal
structure of a new high-calcium form of annexin V. J. Mol. Biol. 234:
816–825.
36. Schiltz, M., T. Prange´, and R. Fourme. 1994. On the preparation
and x-ray data collection of isomorphous xenon derivatives. J. Appl.
Crystallogr. 27:950–960.
37. Otwinowski, Z., and W. Minor. 1997. Processing of x-ray diffraction
data collected in the oscillation mode.Methods Enzymol. 276:307–326.
38. Collaborative Computational Project, N. 1994. The CCP4 suite:
programs for protein crystallography. Acta Crystallogr. D50:760–763.
39. Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Reﬁnement
of macromolecular structures by the Maximum-Likelihood method.
Acta Crystallogr. D53:240–255.
40. Retailleau, P., N. Colloc’h, D. Vivare`s, F. Bonnete´, B. Castro, M. El
Hajji, J. P. Mornon, G. Monard, and T. Prange´. 2004. Complexed and
ligand-free high-resolution structures of urate oxidase (Uox) from
Aspergillus ﬂavus: a reassignment of the active-site binding mode. Acta
Cryst. D60:453–462.
41. Swairjo, M. A., N. O. Concha, M. A. Kaetzel, J. R. Dedman, and B. A.
Seaton. 1995. Ca(21)-bridging mechanism and phospholipid head
group recognition in the membrane-binding protein annexin V. Nat.
Struct. Biol. 2:968–974.
42. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991.
Improved methods for building protein models in electron density
maps and the location of errors in these models. Acta Crystallogr.
A47:110–119.
43. Kleywegt, G. J., and T. A. Jones. 1994. Detection, delineation, mea-
surement and display of cavities in macromolecular structures. Acta
Crystallogr. D50:178–185.
44. Sheldrick, G. M., and T. R. Schneider. 1997. SHELXL: High-
resolution reﬁnement. Methods Enzymol. 227:319–343.
45. Binkowski, T. A., S. Naghibzadeh, and J. Liang. 2003. CASTp:
Computed Atlas of Surface Topography of proteins. Nucleic Acids Res.
31:3352–3355.
46. Sauer, O., M. Roth, T. Schirmer, G. Rummel, and C. Kratky. 2002.
Low-resolution detergent tracing in protein crystals using xenon or
krypton to enhance x-ray contrast. Acta Crystallogr. D58:60–69.
47. Hubbard, S. J., K. H. Gross, and P. Argos. 1994. Intramolecular
cavities in globular proteins. Prot. Eng. 7:613–626.
48. Hubbard, S. J., and P. Argos. 1996. A functional role for protein cavi-
ties in domain: domain motions. J. Mol. Biol. 261:289–300.
49. Carugo, O., and P. Argos. 1998. Accessibility to internal cavities and
ligand binding sites monitored by protein crystallographic thermal
factors. Proteins. 31:201–213.
50. Huber, R., R. Berendes, A. Burger, M. Schneider, A. Karshikov,
H. Luecke, J. Ro¨misch, and E. Paques. 1992. Crystal and molecular
structure of human annexin V after reﬁnement. Implications for
structure, membrane binding and ion channel formation of the annexin
family of proteins. J. Mol. Biol. 223:683–704.
51. Gerke, V., and S. E. Moss. 1997. Annexins and membrane dynamics.
Bioch. Biophys. Acta. 1357:129–154.
52. Sopkova, J., M. Vincent, M. Takahashi, A. Lewit-Bentley, and J.
Gallay. 1999. Conformational ﬂexibility of domain III of annexin V at
membrane/water interfaces. Biochemistry. 38:5447–5458.
53. Johansson, J. S., H. Zou, and J. W. Tanner. 1999. Bound volatile
general anesthetics alter both local protein dynamics and global protein
stability. Anesthesiol. 90:235–245.
54. Dilger, J. P., A. M. Vidal, H. I. Mody, and Y. Liu. 1994. Evidence for
direct actions of general anesthetics on an ion channel protein. A new
look at a uniﬁed mechanism of action. Anesthesiol. 81:431–442.
55. Pratt, M. B., S. S. Husain, K. W. Miller, and J. B. Cohen. 2000.
Identiﬁcation of sites of incorporation in the nicotinic acetylcholine
receptor of a photoactivable general anesthetic. J. Biol. Chem. 275:
29441–29451.
56. Nagele, P., L. B. Metz, and C. M. Crowder. 2004. Nitrous oxide (N2O)
requires the N-methyl-D-aspartate receptor for its action in Caeno-
rhabditis elegans. Proc. Natl. Acad. Sci. USA. 101:8791–8796.
57. David, H. N., M. Ansseau, M. Lemaire, and J. H. Abraini. 2006.
Nitrous oxide and xenon prevent amphetamine-induced carrier-medi-
ated dopamine release in a memantine-like fashion and protect against
behavioral sensitization. Biol. Psychiatry. 60:49–57.
58. Nagele, P., L. B. Metz, and C. M. Crowder. 2005. Xenon acts by
inhibition of non-N-methyl-D-aspartate receptor-mediated glutamater-
gic neurotransmission in Caenorhabditis elegans. Anesthesiol. 103:
508–513.
59. Peoples, R. W., C. Li, and F. F. Weight. 1996. Lipid vs protein theories
of alcohol action in the nervous system. Annu. Rev. Pharmacol.
Toxicol. 36:185–201.
224 Colloc’h et al.
Biophysical Journal 92(1) 217–224
